CoreValve, Inc. Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving® System for Percutaneous Aortic Valve Replacement (PAVR)

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve ( announced today that the expanded clinical evaluation of its ReValving® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

Back to news